Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 1.00 |
| ▸ | MAOB | P27338 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 5/20 | 0.57 |
| ▸ | RAB9A | P51151 | 5/20 | 0.57 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30373802 | 1.00 | MAOA (1.00) | MAOAMAOBNPC1RAB9APTPN11 | |
| Hydrochloric Acid SCHEMBL2085180 | 0.98 | MAOA (0.96) | MAOAMAOBNPC1RAB9APTPN11 | |
| Hydrochloric Acid SCHEMBL4509967 | 0.98 | MAOA (0.96) | MAOAMAOBNPC1RAB9APTPN11 | |
| SCHEMBL11714121 | 0.89 | MAOA (0.79) | MAOAMAOBNPC1RAB9APTPN11 | |
| SCHEMBL29941075 | 0.88 | MAOA (0.79) | MAOAMAOBNPC1RAB9APTPN11 | |
| SCHEMBL4493175 | 0.85 | MAOA (0.73) | MAOAMAOBNPC1RAB9APTPN11 | |
| SCHEMBL10557233 | 0.85 | MAOA (0.73) | MAOAMAOBNPC1RAB9APTPN11 | |
| SCHEMBL20837976 | 0.85 | MAOA (1.00) | MAOAMAOBNPC1RAB9APTPN11 | |
| SCHEMBL2397577 | 0.85 | MAOA (0.73) | MAOAMAOBNPC1RAB9APTPN11 | |
| SCHEMBL7079919 | 0.85 | MAOA (0.73) | MAOAMAOBNPC1RAB9APTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140294724-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROTEINOPATHIES | INTELLECT NEUROSCIENCES, INC. (US) | 2014-10-02 | — | — | US | claimed |
| US-6657065-B2 | Which are useful as microsomal triglyceride transfer protein (MTP) inhibitors | PFIZER INC | 2003-12-02 | — | — | US | claimed |
| US-20020161233-A1 | Methods of making quinoline amides | TOM NORMA J (US) | 2002-10-31 | — | — | US | claimed |
| US-20020042516-A1 | Methods of making quinoline amides | TOM NORMA J (US) | 2002-04-11 | — | — | US | claimed |
| CN-112409188-B | Method for synthesizing N-alkylamine | 南京理工大学 | 2023-05-05 | — | — | CN | disclosed |
| CN-112409188-A | Method for synthesizing N-alkylamine | 南京理工大学 | 2021-02-26 | — | — | CN | disclosed |
| US-10793653-B2 | Process for preparing conjugated diene (co)polymers in the presence of a catalytic system comprising a pyridyl iron (III) complex | VERSALIS S.P.A. (IT) | 2020-10-06 | — | — | US | disclosed |
| CN-107001501-B | Oxo-nitrogenated vanadium complex, catalytic system comprising same and process for (co) polymerizing conjugated dienes | 维尔萨利斯股份公司 | 2020-06-23 | — | — | CN | disclosed |
| US-10654952-B2 | Nitrogen titanium complex, catalytic system comprising said nitrogen titanium complex and process for the (co)polymerization of conjugated dienes | VERSALIS S.P.A. (IT) | 2020-05-19 | — | — | US | disclosed |
| US-10464901-B2 | Composition including benzene diamine derivative for preventing or treating degenerative brain diseases | UNIST(ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY) (KR) | 2019-11-05 | — | — | US | disclosed |
| EP-3237463-B1 | OXO-NITROGENATED VANADIUM COMPLEX, CATALYTIC SYSTEM COMPRISING SAID OXO-NITROGENATED VANADIUM COMPLEX AND PROCESS FOR (CO)POLYMERISING CONJUGATED DIENES | VERSALIS SPA (IT) | 2019-10-23 | — | — | EP | disclosed |
| EP-3194409-B1 | PYRIDINE COMPLEX OF ZIRCONIUM, CATALYTIC SYSTEM COMPRISING SAID PYRIDINE COMPLEX OF ZIRCONIUM AND PROCESS OF (CO)POLYMERIZATION OF CONJUGATED DIENES | VERSALIS SPA (IT) | 2019-09-11 | — | — | EP | disclosed |
| US-4839369-A | ANTIINFLAMMATORY AGENTS; ANTIALLERGENS | RORER PHARMACEUTICAL CORPORATION (US) | 1989-06-13 | — | — | US | disclosed |
| US-4728668-A | Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments | USV PHARMACEUTICAL CORPORATION (US) | 1988-03-01 | — | — | US | disclosed |
| US-4725619-A | Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments | USV PHARMACEUTICAL CORPORATION (US) | 1988-02-16 | — | — | US | disclosed |
| US-4631287-A | Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments | USV PHARMACEUTICAL CORP. (US) | 1986-12-23 | — | — | US | disclosed |
| EP-0200101-A2 | Aryl and heteroaryl ethers as agents for the treatment of hypersensitive aliments | USV PHARMACEUTICAL CORPORATION (US) | 1986-11-05 | — | — | EP | disclosed |
| US-4112100-A | INCREASING THE ENDOGENOUS PRODUCTION OF PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-4069224-A | N-(PYRIDYLALKYL)BENZAMIDES, IMPROVE PRODUCTION OF PROSTAGLANDINS IN MAMMALS | THE UPJOHN COMPANY (US) | 1978-01-17 | — | — | US | disclosed |
| US-4008326-A | INCREASING PRODUCTION OF PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1977-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161233-A1 | Methods of making quinoline amides | CETP, MTTP, LCAT | MAOA 574/4885MAOB 509/4885NPC1 21/4885 |
| US-20020042516-A1 | Methods of making quinoline amides | CETP, MTTP, LCAT | MAOA 574/4885MAOB 509/4885NPC1 21/4885 |
| US-20140294724-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROTEINOPATHIES | CLN6, PSMG3, PSEN1 | MAOA 3567/4885MAOB 3827/4885NPC1 470/4885 |
| US-10793653-B2 | Process for preparing conjugated diene (co)polymers in the presence of a catalytic system comprising a pyridyl iron (III) complex | AOC3, C5, AOC2 | MAOA 33/4885MAOB 25/4885NPC1 3667/4885 |
| US-10464901-B2 | Composition including benzene diamine derivative for preventing or treating degenerative brain diseases | PSEN2, PSEN1, APP | MAOA 158/4885MAOB 74/4885NPC1 439/4885 |
| US-10654952-B2 | Nitrogen titanium complex, catalytic system comprising said nitrogen titanium complex and process for the (co)polymerization of conjugated dienes | CAT, NSFL1C, NCLN | MAOA 72/4885MAOB 61/4885NPC1 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.